A global pharmaceutical company will close a drug manufacturing site in Wilson that employs more than 200 people.
Swiss giant Novartis (NYSE: NVS) told Triangle Business Journal yesterday it plans to close the facility, operated under its generic drug business, Sandoz, by the end of 2023. The site employs around 246 people and specializes in the production of oral solid dosage products, like tablets and capsules, for distribution mostly in the U.S. and Canada.
Novartis began a strategic review…
